Finding the Fit for Immunotherapy in Prostate Cancer

Commentary
Video

Can combining agents turn "cold" prostate cancer tumors "hot"?

Prostate cancer tumors tend to be "cold," meaning that they may have difficulty responding to immunotherapy treatment. But combining agents may help improve their responsiveness, explained Michael Lai, ARNP, a nurse practitioner at Seattle Cancer Care Alliance.

TRANSCRIPTION

So in prostate cancer, we're looking at, for example, immunotherapy and utilizing this in that context. For immunotherapy, what we're doing right now is, as opposed to doing a single-agent model, using dual agents, because prostate cancer can tend to be a relatively "cold" tumor. So if you use something like docetaxel first or in conjunction with immunotherapies like pembrolizumab (Keytruda) or standard-of-care agents such as abiraterone (Zytiga), the idea is: can we warm up the tumor so that the prostate cancer is more susceptible to immunotherapy agents such as pembrolizumab or others.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos
Image of a woman with gray hair and glasses in front of a blue Oncology Nursing News background
Photo of a woman with blond wavy hair wearing a blazer in front of a blue Oncology Nursing News background
Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
Image of a woman with white hair in front of an Oncology Nursing News blue background
Image of a man in a suit standing in front of a blue Oncology Nursing News backdrop
Man in suit standing in front of blue watercolor Oncology Nursing News backdrop
Image of a woman in front of a blue Oncology Nursing News-branded backdrop.
Man standing in front of Oncology Nursing News-branded backdrop
a man wearing a suit and tie in front of a green screen with the ONN logo